US › Healthcare

MetaVia Inc. (MTVA)

US · Healthcare · Biotechnology

$1.26-8.03%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.3M

EPS

$-0.90

EPS estimate

$-0.85

EPS came in at -0.90 against a street estimate of -0.85 — a miss of 5.9%.

Key statistics

Market cap

$9.4M

Forward P/E

0.0

P/B

1.58

Book value

$1.04

EPS (TTM)

$-3.65

52-week high

$14.85

52-week low

$0.97

50-day MA

$1.58

200-day MA

$2.18

Beta

0.96

Analyst view

Analysts rate MetaVia Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $19.33.

Shareholding

Insiders

28.61%

Institutions

13.87%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	1.88%
Citadel Advisors Llc	0.93%
Virtu Financial LLC	0.45%
Geode Capital Management, LLC	0.32%
UBS Group AG	0.20%
Scientech Research LLC	0.18%
Aries Wealth Management	0.15%
Vanguard Capital Management, LLC	0.14%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MetaVia Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.